Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study by Rikke Sørensen et al.
RESEARCH ARTICLE Open Access
Duration of clopidogrel treatment and risk of
mortality and recurrent myocardial infarction
among 11 680 patients with myocardial infarction
treated with percutaneous coronary intervention:
a cohort study
Rikke Sørensen1*, Steen Z Abildstrom2,3, Peter Weeke1, Emil L Fosbøl, Fredrik Folke1, Morten L Hansen1,
Peter R Hansen1, Jan K Madsen1, Ulrik Abildgaard1, Lars Køber4, Henrik E Poulsen5,6, Christian Torp-Pedersen1,
Gunnar H Gislason1
Abstract
Background: The optimal duration of clopidogrel treatment after percutaneous coronary intervention (PCI) is
unclear. We studied the risk of death or recurrent myocardial infarction (MI) in relation to 6- and 12-months
clopidogrel treatment among MI patients treated with PCI.
Methods: Using nationwide registers of hospitalizations and drug dispensing from pharmacies we identified 11
680 patients admitted with MI, treated with PCI and clopidogrel. Clopidogrel treatment was categorized in a 6-
months and a 12-months regimen. Rates of death, recurrent MI or a combination of both were analyzed by the
Kaplan Meier method and Cox proportional hazards models. Bleedings were compared between treatment
regimens.
Results: The Kaplan Meier analysis indicated no benefit of the 12-months regimen compared with the 6-months in
all endpoints. The Cox proportional hazards analysis confirmed these findings with hazard ratios for the 12-months
regimen (the 6-months regimen used as reference) for the composite endpoint of 1.01 (confidence intervals 0.81-
1.26) and 1.24 (confidence intervals 0.95-1.62) for Day 0-179 and Day 180-540 after discharge. Bleedings occurred in
3.5% and 4.1% of the patients in the 6-months and 12-months regimen (p = 0.06).
Conclusions: We found comparable rates of death and recurrent MI in patients treated with 6- and 12-months’
clopidogrel. The potential benefit of prolonged clopidogrel treatment in a real-life setting remains uncertain.
Background
Clopidogrel reduces coronary ischemic events in
patients with acute coronary syndrome[1] and after per-
cutaneous coronary intervention (PCI) where the benefi-
cial effect is evident within the first 24 hours of
treatment initiation[2-4]. In the past 5 years there has
been a clear tendency to recommend increased duration
of clopidogrel treatment. Current guidelines recommend
12 months of treatment for all patients after non-ST-
elevation myocardial infarction, ST-elevation myocardial
infarction and after treatment with PCI, in the absence
of a high risk of bleeding[5-7]. The optimal duration of
clopidogrel treatment is a major clinical issue, as clopi-
dogrel, in addition to the desired anti-thrombotic effect,
poses a considerable risk of bleeding. Premature cessa-
tion has been associated with increased risk of thrombo-
tic events, including stent thrombosis[8,9]. No
randomized study has addressed the optimal length of
clopidogrel treatment, and current guidelines rely on the
arbitrary choice of approximately 12 months’ treatment
used in prior studies[1-3]. Notably, the major benefit of
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clopidogrel treatment was observed during the first
months of treatment in these studies[1-4]. The benefit
of clopidogrel may decline with time, but the risk of
bleeding remains; therefore, further studies of the opti-
mal length of treatment are warranted.
In Denmark, the length of clopidogrel treatment has
followed the change in guidelines, increasing from 6
months in 2002-2003 to 12 months after 2004[10]. We
conducted a nationwide study of 11680 PCI treated
patients with acute myocardial infarction (MI) to evalu-
ate additional benefit (death or recurrent MI) and safety
(bleedings) from the increased duration of clopidogrel
treatment.
Methods
Denmark has several nationwide registers that enable sur-
veillance of the Danish population over time. By use of a
personal civil registration number, detailed information
from different registries can be linked on an individual
level. The Danish National Patient Register holds informa-
tion on all admissions to Danish hospitals since 1978.
Every admission is registered by diagnoses according to
the International Classification of Diseases. The Danish
Register of Medicinal Product Statistics contains informa-
tion on all prescriptions dispensed in Danish pharmacies
since 1995, with information of Anatomic Therapeutic
Chemical (ATC) code, strength, and number of tablets
dispensed. Due to partial reimbursement of drug expenses
by the national government-financed health care system,
pharmacies are required to register all dispensed prescrip-
tions, which ensures complete registration nationwide[11].
In Denmark, most cardiovascular pharmaceuticals require
a prescription; however, aspirin is also dispensed over-the-
counter. Patients in chronic aspirin treatment usually
receive aspirin on prescription in order to receive financial
reimbursement. Information of vital status of all citizens is
held in the Civil Register.
Population
We used the Danish National Patient Register to iden-
tify all patients admitted with first-time MI, classified as
International Classification of Diseases-10 codes I21 and
I22, to Danish hospitals between 2002 and 2005. Subse-
quent PCI was identified by the Danish health care clas-
sification system codes KFNG02 and KFNG05. Our
study population consisted of MI patients treated with
clopidogrel and PCI within 30 days after date of admis-
sion. The diagnosis of MI has previously been validated
to have a specificity of 93%[12]. However, the register
cannot accurately distinguish between the diagnoses
non-ST-elevation myocardial infarction and ST-elevation
myocardial infarction. To compensate for this, we classi-
fied the patients into groups according to the time from
admission to PCI treatment; patients treated with PCI
on Day 0-1 after admission and patients treated with
PCI on Day 2-29. Of the patients treated with PCI on
Day 0-1 57.3% were coded as transmural MI (I21.0
-I21.3), 9.2% as subendocardial MI (I21.4), 33.1% with
unspecified MI (I21.9) and 0.4% with other types (I22.0-
I22.9). Corresponding figures for patients treated with
PCI on Day 2-29 were 12.5%, 55.3%, 31.7% and 0.5%.
Co-morbidity was determined according to the modified
Ontario Acute Myocardial Infarction Mortality Predic-
tion Rules by diagnosis from the index admission and
one year before admission[13]. The diagnosis of heart
failure has a low sensitivity in the National Patient Reg-
ister[14]. Therefore, claimed prescriptions of loop diure-
tics 90 days before admission until 90 days after
discharge were used as a proxy for heart failure, a
method used previously[15]. Similarly, diabetes was con-
sidered present in patients claiming a prescription for
glucose-lowering drugs (ATC A10). The following Inter-
national Classification of Diseases-10 codes were used
for the safety endpoint (bleedings): I60-I62, S06.4-06.6,
J94.2, R04, R31, K25.0, K25.2, K25.4, K26.0, K26.2,
K26.4, K27.0, K27.2, K28.0, K28.2, K92.0-92.2, D62, D50.
Clopidogrel treatment and concomitant cardiovascular
pharmacotherapy
Use of clopidogrel was defined as a dispensed prescrip-
tion within 30 days of discharge (ATC code B01AC04).
Mean length of treatment was 172.8 days (standard
deviation 133.2) in 2002-2003 and 319.7 days (standard
deviation 72.0) in 2004-2005, calculated from the pro-
portions of days covered[10]. Subdivision in treatment
periods, with corresponding variance of treatment dura-
tion of 6-months and 12-months treatment, respectively,
is referred to as the 2002-2003 regimen and the 2004-
2005 regimen. The persistence with treatment is shown
in Figure 1. Information of coverage of clopidogrel
tablets on Day 91 and Day 181 after first dispensed pre-
scription of clopidogrel were calculated and used in a
sensitivity analysis.
Concomitant pharmacotherapy with the following
drugs was defined as a prescription dispensed within 90
days of discharge: beta-blockers (ATC code C07), angio-
tensin-converting enzyme inhibitors and angiotensin-II
receptor blockers (ATC code C09), spironolacton (ATC
code C03DA), or vitamin K antagonists (ATC code
B01AA). Statins (ATC code C10AA) were registered as
a prescription dispensed within 180 days after admis-
sion, and aspirin treatment (ATC code B01AC06,
N02BA01) was identified by dispensed prescriptions 90
days before until 90 days after admission.
Outcomes
We studied the effect of clopidogrel treatment in rela-
tion to the following endpoints: 1. all-cause mortality;
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2. recurrent MI, defined as a re-admission to a Danish
hospital with the diagnosis of MI more than 30 days
after discharge from date of admission for MI; and 3.
combined endpoint of death or recurrent MI. Indivi-
duals were followed for 18 months and censored at the
time of the first event. Patients included after July 1,
2005 were followed until December 31, 2006. A safety
endpoint was used to quantify the proportion of patients
experiencing a major bleeding, defined as an admission
to a hospital with a bleeding diagnosis or death caused
by bleeding. The bleedings were assessed up to 18
months of follow-up, individuals were censored at first
bleeding event.
Statistical Analysis
Descriptive statistics and baseline variables are presented
as percentages or means with standard deviation. Chi2
test was used to assess differences between categorical
data; the Student’s t-test was used for continuous data.
For survival analysis we performed landmark-analyses
using the Kaplan-Meier method (until 18 months of fol-
low-up), the first analysis covered Day 0-179 and the
second started on Day 180 after date of admission for
MI, and included patients alive and without events at
this time point. The time of the landmark analysis was
chosen because the mean duration of treatment in the
2002-2003 regimen was172.8 days (standard deviation
133.2) and was performed to illustrate the potential gain
from the extended clopidogrel treatment in the 2004-
2005 regimen (mean treatment 319.7 days, standard
deviation 72.0)[10]. Adjusted event rates were estimated
by Cox proportional hazards models, using the 2002-
2003 regimen as reference, adjusted for the following
variables: age, sex, concomitant cardiovascular treatment
(use of b-blockers, angiotensin-converting enzyme inhi-
bitors, angiotensin II receptor blockers, statins, loop-
diuretics, glucose-lowering drugs, vitamin K antagonists,
aspirin), and co-morbidity (cerebral vascular disease,
cardiac dysrythmias, diabetes with complications, acute
renal failure, chronics renal failure, malignancy, shock,
pulmonary odema). To match the population of the
landmark analyses, the 2004-2005 regimen was split into
two time-dependent variables: Clopidogrel treatment
Day 0-180 and Clopidogrel treatment Day 180-540.
Patients treated with PCI on Day 0-1 and Day 2-29
were analysed separately. The proportional hazard-
assumption, linearity of continuous variables and lack of
interactions, were found to be valid. Due to less favour-
able persistence with clopidogrel treatment in the 2002-
2003 regimen, a sensitivity analysis was performed. The
sensitivity landmark analysis compared the endpoint
among patients with or without clopidogrel treatment at
Figure 1 Persistence with clopidogrel treatment.
Sørensen et al. BMC Cardiovascular Disorders 2010, 10:6
http://www.biomedcentral.com/1471-2261/10/6
Page 3 of 10
Day 91 and Day 181. Corresponding Cox analyses of
these patients were made, with no clopidogrel treatment
used as reference.
All statistical calculations were performed using the
SAS statistical software package, version 9.1 for Win-
dows (SAS Institute Inc., Cary, NC, USA).
Ethics
Retrospective register studies do not require ethical
approval in Denmark. The study was approved by the
Danish Data Protection Agency (ref: 2003-54-1269).
Results
Baseline characteristics
Between 2002 and 2005, a total of 11680 patients were
hospitalised with a first-time diagnosis of MI, were trea-
ted with PCI within 30 days and dispensed a prescription
of clopidogrel within 30 days after discharge (Figure 2).
Baseline characteristics are shown in Additional file 1.
Landmark analyses: effect of different duration of
clopidogrel treatment
Results of the landmark analyses are shown in Figure 3
and 4. The landmark analyses showed no differences in
death, recurrent MI or the combined endpoint, when
comparing the 2002-2003 regimen with the 2004-2005
regimen among patients treated with PCI Day 0-1. Like-
wise, the landmark analyses among patients treated inva-
sively on Day 2-29 showed no differences in rates of death
Figure 2 The study population.
Figure 3 Landmark analyses using the Kaplan Meier Methods
for patients with PCI on Day 0-1. Patients event-free on Day 180
were included in the second analysis.
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or combined endpoint. For recurrent MI there was a
reduced occurrence among patients treated during 2004-
2005 within the first 180 days of treatment (p = 0.05).
Cox proportional hazard analyses
The Cox proportional hazards models showed no differ-
ence between the 2002-2003 regimen and the 2004-2005
regimen in all endpoints (Figure 5). This applied to both
patients with PCI Day 0-1 and Day 2-29.
Safety
We found a total of 440 (3.8%) hospitalizations for
bleedings or deaths caused by bleeding within 18
months after discharge, evenly distributed between
patients treated with PCI on Day 0-1 and Day 2-29. In
the 2002-2003 regimen, 176 (3.5%) patients had bleed-
ings, corresponding to 264 (4.1%) patients in the 2004-
2005 regimen (p = 0.06).
Sensitivity analyses
Among patients treated with PCI Day 0-1, a total of
1719 were without clopidogrel treatment Day 91 and
1828 without clopidogrel treatment Day181. Of these
73.7% and 71.1% were admitted during 2002-2003,
respectively. Among patients treated with PCI day 2-29,
1214 and 1363 were without clopidogrel treatment Day
91 and Day 181 (79.6% and 74.9% were admitted during
2002-2003). Results of the sensitivity landmark analyses
and the sensitivity Cox proportional hazards model are
shown in Table 1.
Discussion
This nationwide study of PCI treated MI patients exam-
ined the difference in effect and safety of 6- and 12-
months clopidogrel treatment. The main result is that
clopidogrel treatment beyond 6 months provided no
benefit in rates of death, recurrent MI or a combined
endpoint. We found a trend of increased number of
bleedings among patients treated in the 2004-2005 regi-
men compared with those treated with the 2002-2003
regimen (p = 0.06).
Several studies have addressed the question of differ-
ent durations of clopidogrel treatment after acute cor-
onary syndrome and PCI[2,3,16,17]. Eisenstein et al
reported benefit of 12 months treatment compared
with 6 months in patients treated with drug-eluting
stents and concluded that at least 12 months’ treat-
ment was appropriate in this group of patients with
lifelong treatment as a possibility. Patients treated with
bare-metal stents had no advantage in respect to
recurrent MI or death with clopidogrel treatment >6
months[16]. The main weakness of the study by Eisen-
stein et al is that the choice of 6 or 12 months’ treat-
ment for the patient was based on a decision by the
Figure 4 Landmark analyses using the Kaplan Meier Methods
for patients with PCI on day 2-29. Patients event-free on Day 180
were included in the second analysis.
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patient or the physician and was thus subject to con-
founding by indication. In comparison, our study
avoided this selection of patients as we compared dif-
ferent treatment regimens based on standardized
recommendations. The randomized Clopidogrel for the
Reduction of Events During Observation (CREDO)
trial found that 12 months’ clopidogrel treatment was
superior to 2-4 weeks of treatment[3]. The PCI-CURE
trial revealed a superior effect of combined treatment
with aspirin and clopidogrel vs. aspirin in non-ST-ele-
vation MI/acute coronary syndrome patients treated
with PCI. The main benefit was observed from Day 2
to Day 30. Considering the period from PCI to end of
follow-up, the PCI-CURE investigators found less
occurrence of MI in the clopidogrel + aspirin group
but comparable mortality-rates between the groups.
However, the trial did not report the additional reduc-
tion of events that happened from Day 30 after PCI to
end of follow-up, as no landmark analysis was pre-
sented. In the PCI-CURE study all stent-treated PCI
patients received 2-4 weeks open-label clopidogrel fol-
lowed by the randomized study drug[2]. Eisenstein et
Figure 5 Results of Cox proportional hazards Model*: 5A illustrates patients treated with PCI on Day 0-1 and 5B patients treated on Day 2-
29. * The models were adjusted for age, sex, co-morbidities (cerebral vascular disease, diabetes with complications, cardiac dysrythmias, acute
renal disease, chronic renal disease, malignancy, shock, pulmonary odema), concomitant medications (b-blockers, angiotensin-converting enzyme
inhibitors and angiotensin-II receptor blockers, statins, loop diuretics, antidiabetic medication, vitamin K antagonists, aspirin).
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al, the CREDO study and the PCI-CURE study did not
report differences in event rates between 6- and 12-
months’ treatment, hence a direct comparison with our
study is not possible.
In our sensitivity analysis, where persistence with treat-
ment was ensured, we found no additional effect of 12
months treatment compared with 6 months treatment
among patients with PCI Day 0-1. In patients treated with
PCI Day 2-29, a reduced mortality was found among
patients in clopidogrel treatment more than 6 months
(Log rank p = 0.001, HR 0.55 (CI 0.35-0.86), p-value 0.01).
Thus, the sensitivity analyses confirm the findings from
the main analysis, except in patients treated with PCI day
2-29, where we found an effect on mortality. However,
this result should be interpreted with caution, since it
could be due to selection bias of low risk patients (with no
endpoint the first six month of the study).
Other studies have focused on variations in clinical
outcome between different stent-types (bare-metal
stents and drug-eluting stents) and found small differ-
ences in early and late event rates[9,16,18,19]. In these
studies the information on use of clopidogrel is often
inadequate, and some have referred to written guide-
lines[18,19]. In our study we have no information on
the stent types used, but another Danish study using a
regional register from 2002 to mid-2005 reported the
use of drug-eluting stents to be 0% in 2002 increasing
to 75% in 2005[19]. We considered the effect of differ-
ent durations of clopidogrel treatment on a population
level in PCI treated MI patients, with regard to recur-
rent MI and all-cause mortality. Knowledge of the
stent types and coronary lesions would have given a
more detailed picture of the patients’ risk profiles. The
effect of prolonged clopidogrel treatment should be
interpreted in the context of a substantial change of
stent use in the same period and the lack of knowledge
of the stent types used is a limitation of our study. An
increased use of drug-eluting stents would possibly
Table 1 Sensitivity analysis
PCI Day 0-1 PCI Day 2-29
Landmark analyses Log rank P-value Log rank P-value
Day 91-180
Death 0.11 0.002




Recurrent MI 0.33 0.99
Combined 0.65 0.1
Cox Proportional Hazards Model HR (CI)* P-value HR (CI)* P-value
Day 91-180
Death
No clopidogrel 1.00 1.00
Clopidogrel 0.49 (0.23-0.97) 0.04 0.28 (0.12-0.64) 0.003
Recurrent MI
No clopidogrel 1.00 1.00
Clopidogrel 0.71 (0.42-1.19) 0.19 0.75 (0.40-1.38) 0.35
Combined
No clopidogrel 1.00 1.00
Clopidogrel 0.66 (0.43-1.02) 0.06 0.62 (0.37-1.04) 0.07
Day 181-540
Death
No clopidogrel 1.00 1.00
Clopidogrel 0.83 (0.55-1.23) 0.34 0.55 (0.35-0.86) 0.01
Recurrent MI
No clopidogrel 1.00 1.00
Clopidogrel 1.17 (0.76-1.81) 0.48 0.79 (0.50-1.24) 0.3
Combined
No clopidogrel 1.00 1.00
Clopidogrel 0.92 (0.68-1.25) 0.58 0.73 (0.53-1.02) 0.07
* Hazard ratio (confidence intervals).
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give more in-stent thromboses and thus more recur-
rent MIs[9,18,19]. Our results showed both unchanged
rates of mortality and recurrent MIs. A meta-analysis
by De Luca et al of ST-elevation MI patients treated
with either bare-metal stents or drug-eluting stents
compared short duration of clopidogrel treatment (3-9
months) with 12 months’ treatment and found, like
our study, no differences in respect to recurrent MI,
death or a combination of these, between the stent
types and different duration of clopidogrel treatment
[17].
The risk of bleeding is increased with use of antith-
rombotic medication. However, there are conflicting
results from both randomized and observational stu-
dies regarding bleeding risk[1-3,20]. The Clopidogrel
for High Atherothrombotic Risk and Ischemic Stabili-
zation, Management, and Advoidance (CHARISMA)
trial tested long-term treatment in patients at high risk
of atherothrombotic events[21]. Among the sympto-
matic patients, they found a significant increase of
moderate bleedings[21]. The PCI-CURE and the
CHARISMA study reported event rates of major bleed-
ings of 1.6-2.7% [2,21] whereas the CREDO study had
event rates of 6.7 to 8.8%[3]. Major bleedings in the
CREDO trial were slightly differently defined than in
the PCI-CURE and CHARISMA trial, which could
explain some of the variation. In our study the average
event rate for patients treated on both Day 0-1 and
Day 2-29 was 3.8%. Our observed bleeding rates were
higher than those reported from most randomized
trials, although not as high as reported in the CREDO
trial. This could be explained by the real-life setting of
our study.
Strengths and Limitations
The main strength of our study is the completeness of
data, with a complete and unselected cohort of patients
followed in a real-life setting. We had exact information
on clopidogrel use, by individual-level linkage to dis-
pensed prescriptions and complete data on events.
Treatment duration and persistence with clopidogrel
was calculated individually[10]. The concordance
between drug dispensing and drug consumption is likely
to be very high, since reimbursement of drug expenses
is only partial in Denmark. In Denmark, aspirin can be
bought as a prescribed drug as well as over-the-counter.
In our study, we assessed aspirin use by dispensed pre-
scriptions since patients in chronic treatment usually
receive aspirin on prescription in order to receive finan-
cial reimbursement. This occurrence is substantiated by
the high baseline use of aspirin seen in the study popu-
lation (92.6%).
The main limitations of our study are inherent in the
observational nature of the study. We have no
information on important prognostic factors i.e. lipid
levels, smoking status, or left ventricular systolic func-
tion, stent types used, coronary lesions and the treat-
ment given during index admission, e.g. loading dose
of aspirin and clopidogrel, treatment with glycoprotein
IIb/IIIa inhibitors, and heparins. These factors, may
have influenced the results and affected the decision
by the physician to prescribe clopidogrel for a shorter
or a longer period[2,22,23]. During the study period
there were slight changes in the baseline characteristics
of the population. However, we do not believe this had
a major effect on our conclsions. More patients were
treated invasively in close connection to the diagnosis
of MI during the later period, with 58.5% treated Day
0-1 in 2002-2003 increasing to 63.9% in 2004-2005.
This change of practice can be explained by an adapta-
tion to national guidelines, which were altered after
publication of the Danish Multicenter Randomized
Study on Fibrinolytic Therapy versus Acute Coronary
Angioplasty in Acute Myocardial Infarction II trial[24].
In our analyses we stratified the patients according to
the time of PCI, which limited the influence on the
results. We were unable to accurately distinguish
between the diagnoses of non-ST-elevation myocardial
infarction and ST-elevation myocardial infarction and
despite we stratified the patients according to the time
of PCI treatment, this is a limitation. Throughout the
period a change of age and use of concomitant medical
treatment were seen. We included both age and var-
ious concomitant medications in the Cox proportional
hazards models to eliminate confounding by these vari-
ables, but effect of residual confounding cannot fully
be excluded.
Conclusions
This study found no beneficial effect on mortality and
recurrent MI of the 12 months’ clopidogrel treatment
compared with 6 months’ treatment in an unselected
cohort of MI patients treated with PCI. Increased dura-
tion of treatment was associated with a trend toward
increased occurrence of bleedings. More studies are
needed to determine the potential benefits of prolonged
clopidogrel treatment in a real-life setting.
Additional file 1: Baseline characteristics. This file contains baseline
information (year of admission, sex, age, co-morbidity, concomitant
medical treatment). The patients are stratified according to PCI status.




(PCI): Percutaneous coronary intervention; (MI): Acute Myocardial Infarcrion;
(ATC): Anatomic Therapeutic Chemical; (CREDO): Clopidogrel for the
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Reduction of Events During Observation trial; (CHARISMA): The Clopidogrel
for High Atherothrombotic Risk and Ischemic Stabilization, Management, and
Advoidance trial.
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